Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...

7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...

Africa is contributing to groundbreaking data from the PURPOSE 2 study, which explores twice-yearly lenacapavir for HIV ...

New titles from mind-body-spirit publishers draw from ancient wisdom and current science to help readers with everything from ...

The haemorrhagic fever has now killed 11 people in Rwanda, with at least 25 more patients still fighting for their lives in ...

Europe has announced a €2 million project to research long COVID, following €100 million already invested since 2021. Is all ...

New titles from mind-body-spirit publishers draw from ancient wisdom and current science to help readers with everything from healing from trauma to having better sex and getting a good night’s sleep.

“In terms of therapeutics and vaccines, protocol has been finalised and submitted and our national review and ethical ... also plans to use other tools. Gilead Sciences, an American ...

Oct. 4, 2024 /PRNewswire/ -- For the first time since the earliest days of the Covid-19 pandemic, new vehicle inventory has surpassed 3 million according to Cloud Theory's latest "On The Horizon" ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Critical review of the manuscript for important intellectual content ... Funding This paper was funded by grants from the National Natural Science Foundation of China (82070588, 82370577), the ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.